WO1993004043A1 - Anti-hiv (aids) agents - Google Patents
Anti-hiv (aids) agents Download PDFInfo
- Publication number
- WO1993004043A1 WO1993004043A1 PCT/US1992/006525 US9206525W WO9304043A1 WO 1993004043 A1 WO1993004043 A1 WO 1993004043A1 US 9206525 W US9206525 W US 9206525W WO 9304043 A1 WO9304043 A1 WO 9304043A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- compounds
- pharmaceutically acceptable
- compound according
- Prior art date
Links
- 0 *C(C(CC(CCCC1)C1C1)C1OC[C@]([C@](Cc1ccccc1)NC(*NC(C1C(CCCCC2)C2=C(CCCC2)C2CC1)=O)=O)O)=O Chemical compound *C(C(CC(CCCC1)C1C1)C1OC[C@]([C@](Cc1ccccc1)NC(*NC(C1C(CCCCC2)C2=C(CCCC2)C2CC1)=O)=O)O)=O 0.000 description 15
- WPHGSKGZRAQSGP-UHFFFAOYSA-N C1C2C1CCCC2 Chemical compound C1C2C1CCCC2 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- ZJDNQYBPDQZJNL-UHFFFAOYSA-N C=C1C(C(N)=O)=CC=CC1 Chemical compound C=C1C(C(N)=O)=CC=CC1 ZJDNQYBPDQZJNL-UHFFFAOYSA-N 0.000 description 1
- UEPHFJCADQSTPJ-OPWSDZRHSA-N CC(C)(C)OC(NC(CCc1ccccc1)CCS[C@H](CCC1)[C@@H]1C(Nc1ccccc1)=O)=O Chemical compound CC(C)(C)OC(NC(CCc1ccccc1)CCS[C@H](CCC1)[C@@H]1C(Nc1ccccc1)=O)=O UEPHFJCADQSTPJ-OPWSDZRHSA-N 0.000 description 1
- BISRSBCDQPYOSA-KNVGNIICSA-N CC(C)(C)OC(N[C@@H](Cc1ccccc1)C1(C)OC1)=O Chemical compound CC(C)(C)OC(N[C@@H](Cc1ccccc1)C1(C)OC1)=O BISRSBCDQPYOSA-KNVGNIICSA-N 0.000 description 1
- RRLGYTJYFYUAIY-UONOGXRCSA-N CC(C)(C)OC(N[C@H]([C@@H]1OC1)C#Cc1ccccc1)=O Chemical compound CC(C)(C)OC(N[C@H]([C@@H]1OC1)C#Cc1ccccc1)=O RRLGYTJYFYUAIY-UONOGXRCSA-N 0.000 description 1
- WJFKPRGVZBSOBD-LURJTMIESA-N CC[C@@H]1[IH]CCC1 Chemical compound CC[C@@H]1[IH]CCC1 WJFKPRGVZBSOBD-LURJTMIESA-N 0.000 description 1
- VRTABPFAYJJDJP-OLAJPAIPSA-N NC(C[C@@H](C(O)=O)NC(C1(CCCCC2)N2C(CCCC2)C2CC1)=O)=O Chemical compound NC(C[C@@H](C(O)=O)NC(C1(CCCCC2)N2C(CCCC2)C2CC1)=O)=O VRTABPFAYJJDJP-OLAJPAIPSA-N 0.000 description 1
- UXLLNSCRRXSICZ-UHFFFAOYSA-N O=C(C(CCC1)C1SC(c1ccccc1)=O)Nc1ccccc1 Chemical compound O=C(C(CCC1)C1SC(c1ccccc1)=O)Nc1ccccc1 UXLLNSCRRXSICZ-UHFFFAOYSA-N 0.000 description 1
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N OC(c1ccccc1S)=O Chemical compound OC(c1ccccc1S)=O NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/24—Anthracenes; Hydrogenated anthracenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/193,161 US5516784A (en) | 1991-08-13 | 1992-02-15 | Anti-HIV (AIDS) agents |
EP92918437A EP0599983A1 (en) | 1991-08-13 | 1992-08-11 | Anti-hiv (aids) agents |
JP5504333A JPH06510041A (en) | 1991-08-13 | 1992-08-11 | Anti-HIV (AIDS) drugs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74412691A | 1991-08-13 | 1991-08-13 | |
US744,126 | 1991-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993004043A1 true WO1993004043A1 (en) | 1993-03-04 |
Family
ID=24991531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/006525 WO1993004043A1 (en) | 1991-08-13 | 1992-08-11 | Anti-hiv (aids) agents |
Country Status (6)
Country | Link |
---|---|
US (1) | US5516784A (en) |
EP (2) | EP0599983A1 (en) |
JP (1) | JPH06510041A (en) |
AU (1) | AU2469092A (en) |
CA (1) | CA2115581A1 (en) |
WO (1) | WO1993004043A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017096A1 (en) * | 1993-01-17 | 1994-08-04 | Schering Corporation | Peptides having anti-hiv activity |
US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5527829A (en) * | 1994-05-23 | 1996-06-18 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5559256A (en) * | 1992-07-20 | 1996-09-24 | E. R. Squibb & Sons, Inc. | Aminediol protease inhibitors |
WO1997034894A1 (en) * | 1996-03-15 | 1997-09-25 | Biochem Pharma Inc. | Naphthyridine derivatives and their analogues inhibiting cytomegalovirus |
US5705647A (en) * | 1996-09-05 | 1998-01-06 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors |
US5846993A (en) * | 1992-12-22 | 1998-12-08 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
EP0901480A1 (en) * | 1996-05-07 | 1999-03-17 | Boehringer Ingelheim Pharmaceuticals Inc. | Process for preparing oxiranemethanamine derivatives |
US5945431A (en) * | 1996-03-15 | 1999-08-31 | Biochem Therapeutics Incorporated | Cytomegalovirus inhibiting compounds |
US5962725A (en) * | 1996-09-05 | 1999-10-05 | Agouron Pharmaceuticals, Inc. | Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir |
WO1999059582A1 (en) * | 1998-05-19 | 1999-11-25 | Centaur Pharmaceuticals, Inc. | Amide therapeutics for the treatment of inflammatory bowel disease |
US6001851A (en) * | 1997-03-13 | 1999-12-14 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US6008228A (en) * | 1995-06-06 | 1999-12-28 | Hoffman-La Roche Inc. | Pharmaceutical compositions containing proteinase inhibitors |
US6084107A (en) * | 1997-09-05 | 2000-07-04 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors |
US6117999A (en) * | 1996-09-05 | 2000-09-12 | Agouron Phramaceuticals, Inc. | Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors |
US6992177B1 (en) | 2004-12-10 | 2006-01-31 | Roche Diagnostics Operations, Inc. | Saquinavir derivatives useful in immunoassay |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69333270T2 (en) | 1992-03-11 | 2004-08-05 | Narhex Ltd. | AMINE DERIVATIVES OF OXO AND HYDROXY SUBSTITUTED CARBON HYDROGEN |
US6071895A (en) | 1992-03-11 | 2000-06-06 | Narhex Limited | Polar-substituted hydrocarbons |
US5888992A (en) * | 1992-03-11 | 1999-03-30 | Narhex Limited | Polar substituted hydrocarbons |
WO1993018006A1 (en) * | 1992-03-11 | 1993-09-16 | Narhex Limited | Amine derivatives of oxo- and hydroxy-substitued hydrocarbons |
US5434265A (en) * | 1992-12-22 | 1995-07-18 | Eli Lilly And Company | Inhibitors of HIV protease |
IL110898A0 (en) * | 1993-09-10 | 1994-11-28 | Narhex Australia Pty Ltd | Polar-substituted hydrocarbons |
WO1998042656A1 (en) * | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
JP4250335B2 (en) | 1998-01-28 | 2009-04-08 | 日本化薬株式会社 | Process for producing optically active threo-3-amino-1,2-epoxy compound |
CA2360740A1 (en) * | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
ATE343562T1 (en) * | 2000-03-23 | 2006-11-15 | Elan Pharm Inc | COMPOUNDS AND METHODS FOR TREATING ALZHEIMER'S DISEASE |
US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
EP1666452A2 (en) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
US20030096864A1 (en) * | 2000-06-30 | 2003-05-22 | Fang Lawrence Y. | Compounds to treat alzheimer's disease |
CN1217920C (en) | 2000-06-30 | 2005-09-07 | 艾兰制药公司 | Compounds to treat alzheimer's disease |
US6846813B2 (en) * | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
PE20020276A1 (en) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER |
MXPA04000140A (en) * | 2001-06-27 | 2004-06-03 | Elan Pharm Inc | Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease. |
KR101383197B1 (en) * | 2006-05-11 | 2014-04-09 | 에스피아이 레이저스 유케이 리미티드 | Apparatus for providing optical radiation |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0270234A2 (en) * | 1986-10-31 | 1988-06-08 | Pfizer Inc. | Renin inhibitors |
EP0310918A2 (en) * | 1987-10-06 | 1989-04-12 | F. Hoffmann-La Roche Ag | Peptide-like amino-acid derivatives |
EP0346847A2 (en) * | 1988-06-13 | 1989-12-20 | F. Hoffmann-La Roche Ag | Amino acid derivatives |
EP0399556A1 (en) * | 1989-05-26 | 1990-11-28 | Warner-Lambert Company | Amino-substituted heterocycles as renin inhibitors |
EP0401676A1 (en) * | 1989-06-06 | 1990-12-12 | Bio-Mega/Boehringer Ingelheim Research Inc. | Enzyme inhibitors |
EP0431520A2 (en) * | 1989-12-04 | 1991-06-12 | G.D. Searle & Co. | Heterocyclic acyl aminodiol beta-amino acid derivatives |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2010531A1 (en) * | 1989-03-06 | 1990-09-06 | Werner Neidhart | Amino acid derivatives |
US5256677A (en) * | 1989-05-23 | 1993-10-26 | Abbott Laboratories | Retroviral protease inhibiting compounds |
-
1992
- 1992-02-15 US US08/193,161 patent/US5516784A/en not_active Expired - Fee Related
- 1992-08-11 EP EP92918437A patent/EP0599983A1/en not_active Withdrawn
- 1992-08-11 JP JP5504333A patent/JPH06510041A/en active Pending
- 1992-08-11 WO PCT/US1992/006525 patent/WO1993004043A1/en not_active Application Discontinuation
- 1992-08-11 CA CA002115581A patent/CA2115581A1/en not_active Abandoned
- 1992-08-11 EP EP92307344A patent/EP0533342A1/en active Pending
- 1992-08-11 AU AU24690/92A patent/AU2469092A/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0270234A2 (en) * | 1986-10-31 | 1988-06-08 | Pfizer Inc. | Renin inhibitors |
EP0310918A2 (en) * | 1987-10-06 | 1989-04-12 | F. Hoffmann-La Roche Ag | Peptide-like amino-acid derivatives |
EP0346847A2 (en) * | 1988-06-13 | 1989-12-20 | F. Hoffmann-La Roche Ag | Amino acid derivatives |
EP0399556A1 (en) * | 1989-05-26 | 1990-11-28 | Warner-Lambert Company | Amino-substituted heterocycles as renin inhibitors |
EP0401676A1 (en) * | 1989-06-06 | 1990-12-12 | Bio-Mega/Boehringer Ingelheim Research Inc. | Enzyme inhibitors |
EP0431520A2 (en) * | 1989-12-04 | 1991-06-12 | G.D. Searle & Co. | Heterocyclic acyl aminodiol beta-amino acid derivatives |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5559256A (en) * | 1992-07-20 | 1996-09-24 | E. R. Squibb & Sons, Inc. | Aminediol protease inhibitors |
US5837710A (en) * | 1992-12-22 | 1998-11-17 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US6271235B1 (en) | 1992-12-22 | 2001-08-07 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5952343A (en) * | 1992-12-22 | 1999-09-14 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5859002A (en) * | 1992-12-22 | 1999-01-12 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5824688A (en) * | 1992-12-22 | 1998-10-20 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5852043A (en) * | 1992-12-22 | 1998-12-22 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5827858A (en) * | 1992-12-22 | 1998-10-27 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5846993A (en) * | 1992-12-22 | 1998-12-08 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5834467A (en) * | 1992-12-22 | 1998-11-10 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
WO1994017096A1 (en) * | 1993-01-17 | 1994-08-04 | Schering Corporation | Peptides having anti-hiv activity |
US5693815A (en) * | 1993-01-17 | 1997-12-02 | Schering Corporation | Peptides |
US6693199B2 (en) | 1993-10-07 | 2004-02-17 | Agouron Pharmaceuticals, Inc. | Method of making HIV protease inhibitors |
US5827859A (en) * | 1993-10-07 | 1998-10-27 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5827891A (en) * | 1993-10-07 | 1998-10-27 | Agouron Pharmaceuticals, Inc. | HIV protease inhibtors |
US6162812A (en) * | 1993-10-07 | 2000-12-19 | Agouron Pharmaceuticals, Inc. | Pharmaceutical compositions containing HIV protease inhibitors and methods of their use |
US6525215B2 (en) | 1993-10-07 | 2003-02-25 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5527829A (en) * | 1994-05-23 | 1996-06-18 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US6008228A (en) * | 1995-06-06 | 1999-12-28 | Hoffman-La Roche Inc. | Pharmaceutical compositions containing proteinase inhibitors |
GB2326412A (en) * | 1996-03-15 | 1998-12-23 | Iaf Biochem Int | Naphthyridine derivatives and their analogues inhibiting cytomegalovirus |
US5945431A (en) * | 1996-03-15 | 1999-08-31 | Biochem Therapeutics Incorporated | Cytomegalovirus inhibiting compounds |
WO1997034894A1 (en) * | 1996-03-15 | 1997-09-25 | Biochem Pharma Inc. | Naphthyridine derivatives and their analogues inhibiting cytomegalovirus |
EP0901480A1 (en) * | 1996-05-07 | 1999-03-17 | Boehringer Ingelheim Pharmaceuticals Inc. | Process for preparing oxiranemethanamine derivatives |
EP0901480A4 (en) * | 1996-05-07 | 1999-11-24 | Boehringer Ingelheim Pharma | Process for preparing oxiranemethanamine derivatives |
US5962725A (en) * | 1996-09-05 | 1999-10-05 | Agouron Pharmaceuticals, Inc. | Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir |
US6512135B2 (en) | 1996-09-05 | 2003-01-28 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors |
US5705647A (en) * | 1996-09-05 | 1998-01-06 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors |
US6605721B2 (en) | 1996-09-05 | 2003-08-12 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors |
US6117999A (en) * | 1996-09-05 | 2000-09-12 | Agouron Phramaceuticals, Inc. | Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors |
US6303786B1 (en) | 1996-09-05 | 2001-10-16 | Agouron Pharmaceuticals, Inc. | Processes for making nelfinavir mesylate |
US6316625B1 (en) | 1996-09-05 | 2001-11-13 | Agouron Pharmaceuticals, Inc. | Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors |
US6392067B1 (en) | 1996-09-05 | 2002-05-21 | Agouron Pharmaceuticals, Inc. | Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors |
US6407285B1 (en) | 1996-09-05 | 2002-06-18 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors and methods for making HIV-protease inhibitors |
US6465661B1 (en) | 1996-09-05 | 2002-10-15 | Agouron Pharmaceuticals, Inc. | Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors |
US6001851A (en) * | 1997-03-13 | 1999-12-14 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US6084107A (en) * | 1997-09-05 | 2000-07-04 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors |
US6271265B1 (en) | 1998-05-19 | 2001-08-07 | Centaur Pharmaceuticals, Inc. | Amide therapeutics for the treatment of inflammatory bowel disease |
WO1999059582A1 (en) * | 1998-05-19 | 1999-11-25 | Centaur Pharmaceuticals, Inc. | Amide therapeutics for the treatment of inflammatory bowel disease |
US6992177B1 (en) | 2004-12-10 | 2006-01-31 | Roche Diagnostics Operations, Inc. | Saquinavir derivatives useful in immunoassay |
Also Published As
Publication number | Publication date |
---|---|
AU2469092A (en) | 1993-03-16 |
JPH06510041A (en) | 1994-11-10 |
EP0533342A1 (en) | 1993-03-24 |
EP0599983A1 (en) | 1994-06-08 |
US5516784A (en) | 1996-05-14 |
CA2115581A1 (en) | 1993-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993004043A1 (en) | Anti-hiv (aids) agents | |
US4584294A (en) | Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents | |
JP3192070B2 (en) | Antiviral ethers of aspartic protease substrate isosteres | |
US20040039016A1 (en) | HIV protease inhibitors | |
EP0386611A2 (en) | Amino acid derivatives | |
EP0365992A1 (en) | Heterocyclic peptide renin inhibitors | |
EP0343654A2 (en) | Diol-containing renin inhibitors | |
US4757069A (en) | Pyridazodiazepine derivatives | |
EP0174162A2 (en) | Pharmaceutically active dipeptide derivatives | |
HU202515B (en) | Process for producing new forscholine derivatives and pharmaceutical compositions comprising such compounds | |
CZ236595A3 (en) | Amide derivatives of 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxyalkanoic acids | |
CZ234498A3 (en) | Aspartylprotease inhibitors, process of their preparation and preparation in which they are comprised | |
US4609494A (en) | 5-acetyl-3,4,5,6-tetrahydro-4-oxo-2,6-methano-2H-1,3,5-benzothiazocine(benzodiazocine)-11-carboxylates useful as calcium channel blockers | |
EP0313847A2 (en) | Non-peptidyl alpha-succinamidoacyl aminodiols as anti-hypertensive agents | |
GB2046259A (en) | Amino-alcohol derivatives and pharmaceutical compositions containing them | |
FI120259B (en) | A process for preparing the epoxide | |
JP2871098B2 (en) | Benzopyrans and pharmaceutical compositions containing them | |
US5188950A (en) | Method of preparing HIV protease inhibitors | |
JPH0249788A (en) | Pyranobenzoxadiazole derivative | |
WO1994017096A1 (en) | Peptides having anti-hiv activity | |
CA2665818A1 (en) | Therapeutic compounds | |
PL179039B1 (en) | Method of manufacturing hiv protease inhibitors | |
ES2198778T3 (en) | NAFTALENE DERIVATIVES | |
JPH0422887B2 (en) | ||
EP0528661A2 (en) | HIV protease inhibitors with N-terminal polyether substituents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992918437 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08193161 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2115581 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1992918437 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992918437 Country of ref document: EP |